Pregnancy and Developmental Outcomes After Transfer of Reportedly Aneuploid or Mosaic Embryos

Launched by STANFORD UNIVERSITY · Sep 27, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at the outcomes of pregnancies that start with embryos considered to be abnormal based on genetic testing. Specifically, it aims to find out how often these embryos, called aneuploid or mosaic embryos, lead to healthy babies being born. The study will also explore if pregnancies from these embryos have a higher chance of complications and if the babies face any increased risks for health or development issues during their first five years of life.

To participate in this trial, women aged between 18 and 42 who have available aneuploid or mosaic embryos and no other suitable embryos can apply. Participants will need to travel to Stanford for treatment and must be fluent in English. The trial is currently recruiting, and those who join can expect to contribute to important research that may help future families understand the risks and outcomes of using these specific types of embryos. It's important to note that embryos with a condition known as triploidy are not eligible for this study.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Available aneuploid or mosaic embryos
• • No other acceptable embryos available
• • Willing to travel to Stanford for treatment
• • English language fluency
• Exclusion Criteria:
• • Use of international donor eggs or sperm not tested according to FDA guidelines.
• • Living outside the United States
• • Embryos with Triploidy are not eligible for transfer in this protocol